LOS ANGELES, Jan. 26, 2024 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Maison Solutions Inc. (“Maison” or the “Company”) (NASDAQ: MSS). Class Period: October 5, 2023 – December 15, 2023 Lead Plaintiff Deadline: March 4, 2024 If… Continue reading MSS Investors Have Opportunity to Lead Maison Solutions Inc. Securities Fraud Lawsuit
Category: Newswire
MBLY Investors Have Opportunity to Lead Mobileye Global Inc. Securities Fraud Lawsuit
LOS ANGELES, Jan. 26, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Mobileye Global Inc. (“Mobileye” or the “Company”) (NASDAQ: MBLY). Class Period: January 26, 2023 – January 3, 2024 Lead Plaintiff Deadline: March 18, 2024 If you… Continue reading MBLY Investors Have Opportunity to Lead Mobileye Global Inc. Securities Fraud Lawsuit
MVST Investors Have Opportunity to Lead Microvast Holdings, Inc. Securities Fraud Lawsuit
LOS ANGELES, Jan. 26, 2024 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Microvast Holdings, Inc. (“Microvast” or the “Company”) (NASDAQ: MVST). Class Period: October 19, 2022 – November 20, 2023 Lead Plaintiff Deadline: February 5, 2024 If… Continue reading MVST Investors Have Opportunity to Lead Microvast Holdings, Inc. Securities Fraud Lawsuit
GM Investors Have Opportunity to Lead General Motors Company Securities Fraud Lawsuit
LOS ANGELES, Jan. 26, 2024 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against General Motors Company (“GM” or the “Company”) (NYSE: GM). Class Period: February 10, 2021 – October 26, 2023 Lead Plaintiff Deadline: February 6, 2024… Continue reading GM Investors Have Opportunity to Lead General Motors Company Securities Fraud Lawsuit
ON Investors Have Opportunity to Lead ON Semiconductor Corporation Securities Fraud Lawsuit
BENSALEM, Pa., Jan. 26, 2024 /PRNewswire/ — Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ON Semiconductor Corporation (“onsemi” or the “Company”) (NASDAQ: ON). Class Period: May 1, 2023 – October 27, 2023 Lead Plaintiff Deadline: February 12, 2024 Investors suffering… Continue reading ON Investors Have Opportunity to Lead ON Semiconductor Corporation Securities Fraud Lawsuit
DADA Investors Have Opportunity to Lead Dada Nexus Limited Securities Fraud Lawsuit
BENSALEM, Pa., Jan. 26, 2024 /PRNewswire/ — Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Dada Nexus Limited (“Dada” or the “Company”) (NASDAQ: DADA). Class Period: May 11, 2023 – January 8, 2024 Lead Plaintiff Deadline: March 11, 2024 Investors suffering… Continue reading DADA Investors Have Opportunity to Lead Dada Nexus Limited Securities Fraud Lawsuit
Concentrated Solar Power Market Report 2024-2034 – Integration of CSP in Hybrid Power Plants Opportunities for the Market
DUBLIN, Jan. 26, 2024 /PRNewswire/ — The “Concentrated Solar Power (CSP) Market Report 2024-2034” has been added to ResearchAndMarkets.com’s offering. Revenue for the global Concentrated Solar Power Market is forecast to surpass US$7.2 billion in 2024. The Concentrated Solar Power (CSP) Market Is Poised for Significant Growth as the Global Shift Toward Sustainable and Renewable… Continue reading Concentrated Solar Power Market Report 2024-2034 – Integration of CSP in Hybrid Power Plants Opportunities for the Market
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival – – If approved, PADCEV with KEYTRUDA would be the first combination in the EU to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line locally advanced or metastatic urothelial cancer – TOKYO and NEW… Continue reading European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
ViewSonic’s 4th ColorPro Awards “RISE”: Fusing Art and Technology in Global Creative Endeavors
Reflecting on a Journey of Personal Growth and Artistic Expression in London, Taipei, and a Notable Debut in Ho Chi Minh City BREA, Calif., Jan. 26, 2024 /PRNewswire/ — ViewSonic Corp., a global leader in visual and EdTech solutions, celebrates the successful conclusion and significant expansion of the 4th ColorPro Awards. Themed “RISE,” this edition… Continue reading ViewSonic’s 4th ColorPro Awards “RISE”: Fusing Art and Technology in Global Creative Endeavors
BRBS Investors Have Opportunity to Lead Blue Ridge Bankshares, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Jan. 26, 2024 /PRNewswire/ — Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Blue Ridge Bankshares, Inc. (“Blue Ridge” or the “Company”) (NYSE: BRBS). Class Period: March 10, 2023 – October 31, 2023 Lead Plaintiff Deadline: February 5,… Continue reading BRBS Investors Have Opportunity to Lead Blue Ridge Bankshares, Inc. Securities Fraud Lawsuit